Our patients met the MCI clinical criteria of the NIA-AA and had neurodegeneration biomarkers (i.e. hippocampal grey matter measures) but more studies including tau or amyloid information will be key to understand how Alzheimer’s disease-specific network disruption may be. The gene discussed is MAPT; the disease is Alzheimer disease.